Tim Shannon Joins SynCardia Systems, Inc. as Executive Vice President, Global Commercialization

Primary tabs

Tim Shannon Joins SynCardia Systems, Inc. as Executive Vice President, Global Commercialization

tweet me:
Tim Shannon Joins .@SynCardia Systems, Inc. as Executive Vice President, Global Commercialization http://goo.gl/KhYWkE

Multimedia from this Release

Tim Shannon joins SynCardia Systems, Inc. as its Executive Vice President, Global Commercialization.

Monday, January 12, 2015 - 4:00pm

CAMPAIGN: SynCardia Systems, Inc.

CONTENT: Press Release

January 12, 2015 /3BL Media/ - SynCardia Systems, Inc. announced today that Tim Shannon joined the company January 5, 2015 as its Executive Vice President, Global Commercialization.

“Mr. Shannon brings to our executive management team at SynCardia over 25 years of global sales, marketing and operational expertise within the medical device space,” says Michael Garippa, CEO and President of SynCardia Systems, Inc. “Mr. Shannon will drive key commercialization initiatives designed to broaden SynCardia’s growth and presence both domestically and internationally. We are very excited to have him in this strategic role within the company.”

SynCardia manufactures the SynCardia temporary Total Artificial Heart, the world’s only FDA, Health Canada and CE approved Total Artificial Heart for patients dying of end-stage biventricular heart failure. It also manufactures the Freedom® portable driver, which powers the SynCardia Heart while giving patients almost unlimited mobility.

Shannon has held senior-level sales and marketing roles at several companies, including Boston Scientific Corp., General Electric Medical Systems, U.S. Surgical Corp. and Teleflex, Inc., where he managed its $225 million vascular products portfolio.

Most recently, Shannon was senior vice president of worldwide sales and marketing at Response Biomedical Corp., a Vancouver-based point-of-care testing company that focused primarily on cardiac markers for the diagnosis of acute myocardial infarction and congestive heart failure.

Additionally, Shannon sits on the Board of Directors for SystemsMerge, Inc., an Orlando-based and privately held medical informatics company.

“I look forward to contributing to the growing success of SynCardia, especially by strengthening global access to the life-saving SynCardia temporary Total Artificial Heart,” says Shannon.

For additional information, please visit: http://www.syncardia.com/

 

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. in Tucson, Arizona is the privately-held owner and manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart for use as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles can no longer pump enough blood for a person to survive.

More than 1,350 implants of the SynCardia Total Artificial Heart account for over 400 patient years of life on the device. Since January 2010 more than 550 SynCardia Hearts have been implanted.

The youngest patient to receive a SynCardia Heart was 9 years old; the oldest was 76 years old. The longest a patient has lived with a SynCardia Heart was nearly four years (1,374 days) before receiving a successful donor heart transplant Sept. 11, 2011.

SynCardia Systems also manufactures the Freedom® portable driver, which powers the SynCardia Heart while allowing clinically stable patients to be discharged from the hospital to live at home and in their communities. The wearable Freedom driver has been used by more than 200 patients, accounting for over 120 years of support.

Contact

Don Isaacs
+1 (520) 955-0660
SynCardia Systems, Inc.
Keywords: Health & Healthcare | Artificial Heart | Boston Scientific Corp | Events, Media & Communications | Freedom portable driver | General Electric Medical Systems | Innovation & Technology | PR | SynCardia | SynCardia Systems | SystemsMerge

CAMPAIGN: SynCardia Systems, Inc.

CONTENT: Press Release

parse.ly